CY1977A - CD 25 binding molecules - Google Patents

CD 25 binding molecules

Info

Publication number
CY1977A
CY1977A CY197797A CY197797A CY1977A CY 1977 A CY1977 A CY 1977A CY 197797 A CY197797 A CY 197797A CY 197797 A CY197797 A CY 197797A CY 1977 A CY1977 A CY 1977A
Authority
CY
Cyprus
Prior art keywords
antibodies
binding molecules
paticularly
immunoconjugates
prophylaxis
Prior art date
Application number
CY197797A
Other languages
English (en)
Original Assignee
Sandoz Ltd 1
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26296798&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1977(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB909005962A external-priority patent/GB9005962D0/en
Priority claimed from GB909019323A external-priority patent/GB9019323D0/en
Application filed by Sandoz Ltd 1 filed Critical Sandoz Ltd 1
Publication of CY1977A publication Critical patent/CY1977A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
CY197797A 1990-03-16 1997-09-05 CD 25 binding molecules CY1977A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909005962A GB9005962D0 (en) 1990-03-16 1990-03-16 Improvements in or relating to organic compounds
GB909019323A GB9019323D0 (en) 1990-09-05 1990-09-05 Improvements relating to immunosuppression

Publications (1)

Publication Number Publication Date
CY1977A true CY1977A (en) 1997-09-05

Family

ID=26296798

Family Applications (1)

Application Number Title Priority Date Filing Date
CY197797A CY1977A (en) 1990-03-16 1997-09-05 CD 25 binding molecules

Country Status (23)

Country Link
US (2) US6521230B1 (fr)
EP (1) EP0449769B1 (fr)
JP (1) JP2585475B2 (fr)
AT (1) ATE98655T1 (fr)
AU (1) AU635401B2 (fr)
CA (1) CA2038279C (fr)
CY (1) CY1977A (fr)
DE (2) DE69100768T2 (fr)
DK (1) DK0449769T3 (fr)
ES (1) ES2061216T3 (fr)
FI (3) FI103131B1 (fr)
HK (1) HK53797A (fr)
HU (2) HUT60768A (fr)
IE (1) IE65062B1 (fr)
IL (1) IL97545A (fr)
LU (1) LU90383I2 (fr)
MY (1) MY106161A (fr)
NL (1) NL990008I2 (fr)
NZ (1) NZ237434A (fr)
PL (1) PL170321B1 (fr)
PT (1) PT97034B (fr)
SA (1) SA92120358B1 (fr)
TW (1) TW213486B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993010819A1 (fr) * 1991-11-26 1993-06-10 Alkermes, Inc. Procede de preparation de conjugues d'agents diagnostiques ou neuropharmaceutiques-anticorps specifiques de recepteur de transferine
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US6024957A (en) * 1993-06-02 2000-02-15 Research Corporation Technologies, Inc. Immunomodulators and methods for the prevention and reversal of organ transplant rejection using same
US6106834A (en) 1993-06-02 2000-08-22 Research Corporation Technologies, Inc. Use of anti-CD45 leukocyte antigen antibodies for immunomodulation
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US6893636B2 (en) * 1997-02-20 2005-05-17 Biogen Idec Ma Inc. Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
US7033589B1 (en) 1997-02-20 2006-04-25 Biogen Idec Ma Inc. γ-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
DE69835216T2 (de) 1997-07-25 2007-05-31 Nichia Corp., Anan Halbleitervorrichtung aus einer nitridverbindung
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
DK1100829T3 (da) * 1998-07-27 2007-12-27 Novartis Ag Anvendelse af basiliximab til behandling af rheumatoid arthritis eller hudsygdomme
US6406695B1 (en) 1998-10-30 2002-06-18 University Of Miami Treatment of hepatitis C by administration of anti-IL-2 receptor monoclonal antibody
WO2000025816A1 (fr) * 1998-10-30 2000-05-11 The University Of Miami Traitement de l'hepatite c par administration d'un anticorps monoclonal anti recepteur de il-2 et d'un compose antiviral
GB9825632D0 (en) 1998-11-23 1999-01-13 Novartis Ag Organic compounds
FR2793691B1 (fr) * 1999-05-21 2003-10-03 Hippocampe Utilisation d'anticorps reconnaissant le recepteur de l'interleukine-2 dans la prevention et/ou le traitement des infections par les virus du sida
GB0007911D0 (en) * 2000-03-30 2000-05-17 Novartis Ag Organic compounds
KR20080110687A (ko) 2001-04-06 2008-12-18 더 유니버시티 오브 브리스톨 스테로이드-내성 환자에서의 ｃｄ25 결합 분자의 용도
US7365168B2 (en) * 2002-10-15 2008-04-29 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217798B2 (en) * 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
US7361740B2 (en) * 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
JP4033390B2 (ja) * 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
NZ540555A (en) 2002-11-15 2008-04-30 Genmab As Antibody therapeutics for treatingand/or preventing diseases associated with cells expressing CD25, including autoimmune diseases, inflammatory and hyperproliferative skin disorders
EP1460088A1 (fr) 2003-03-21 2004-09-22 Biotest AG Anticorps humanisé contre CD4 avec des caractéristiques immunosuppressives
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds
CA2635623C (fr) * 2005-12-30 2015-02-17 Michael Super Anticorps anti-cd19 d'immunogenicite reduite
CN102027016A (zh) 2008-03-13 2011-04-20 生物测试股份公司 一种治疗疾病的试剂
RU2540018C2 (ru) 2008-03-13 2015-01-27 Биотест Аг Средство для лечения заболевания
EP2265643B1 (fr) 2008-03-13 2016-10-19 Biotest AG Schema posologique pour traiter le psoriasis et l'arhtrite rhumatoide
EP4406615A3 (fr) 2009-10-26 2024-12-11 F. Hoffmann-La Roche AG Procédé de production d'une immunoglobuline glycosylée
GB0920944D0 (en) 2009-11-30 2010-01-13 Biotest Ag Agents for treating disease
US20140359902A1 (en) 2011-12-16 2014-12-04 Synthon Biopharmaceuticals B.V. EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED
KR101645905B1 (ko) 2012-10-12 2016-08-04 스피로즌 살 피롤로벤조디아제핀 및 그의 컨주게이트
EP2968585B1 (fr) 2013-03-13 2018-07-18 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
WO2016037644A1 (fr) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US9993452B2 (en) 2014-12-05 2018-06-12 Vireo Systems, Inc. Compositions and methods for treatment of inflammation
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
WO2017096262A1 (fr) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions et procédés pour atténuer ou prévenir une réponse immunitaire à une molécule thérapeutique immunogène chez des primates non humains
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 免疫介在性療法薬を有する抗体−薬物コンジュゲート
WO2018193104A1 (fr) 2017-04-20 2018-10-25 Adc Therapeutics Sa Polythérapie avec un conjugué anticorps-médicament anti-cd25
JP2021524449A (ja) 2018-05-23 2021-09-13 アーデーセー セラピューティクス ソシエテ アノニム 分子アジュバント
GB201811364D0 (en) 2018-07-11 2018-08-29 Adc Therapeutics Sa Combination therapy
KR102789146B1 (ko) * 2019-06-10 2025-04-01 샨동 보안 바이오테크놀로지 컴퍼니, 리미티드 항-cd25 항체 및 이의 적용
GB201917254D0 (en) 2019-11-27 2020-01-08 Adc Therapeutics Sa Combination therapy
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
WO2022165419A1 (fr) 2021-02-01 2022-08-04 Kyverna Therapeutics, Inc. Méthodes pour augmenter la fonction des lymphocytes t
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022221669A1 (fr) 2021-04-15 2022-10-20 Kyverna Therapeutics, Inc. Méthodes et compositions pour traiter une maladie faisant intervenir des lymphocytes t foxp3+ cd4+ cibles et des agents de suicide cellulaire
WO2022078524A2 (fr) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Conjugaison spécifique d'un anticorps
CN114957473B (zh) * 2022-04-25 2023-05-16 苏州旭光科星抗体生物科技有限公司 一种对可溶性cd25蛋白含量检测的酶联免疫检测试剂盒
CA3260127A1 (fr) 2022-07-01 2024-01-04 Neurogene Inc. Variants de neo-2/15 et leurs utilisations pour stimuler de manière préférentielle des cellules t régulatrices

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8605316D0 (en) * 1986-03-04 1986-04-09 Royal Free Hosp School Med Immunosuppression
GB2188941B (en) 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
ES2059539T3 (es) * 1987-12-02 1994-11-16 Becton Dickinson Co Metodo para la prevencion de la enfermedad del injerto frente al huesped.
JPH02503867A (ja) * 1988-04-15 1990-11-15 プロテイン　デザイン　ラブズ　インコーポレーテッド Ｉｌ‐２レセプター特異的キメラ抗体
DE3815472A1 (de) 1988-05-06 1989-11-16 Centre Regional De Transfusion Monoklonaler antikoerper und seine verwendung
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation

Also Published As

Publication number Publication date
EP0449769A1 (fr) 1991-10-02
IE65062B1 (en) 1995-10-04
AU635401B2 (en) 1993-03-18
DE69100768T2 (de) 1994-05-11
FI103131B (fi) 1999-04-30
ATE98655T1 (de) 1994-01-15
DE69100768D1 (de) 1994-01-27
HU211885A9 (en) 1995-12-28
CA2038279A1 (fr) 1991-09-17
ES2061216T3 (es) 1994-12-01
LU90383I2 (fr) 1999-06-07
FI19991788A7 (fi) 1999-08-23
NL990008I1 (nl) 1999-06-01
DE19975033I2 (de) 2007-01-04
PT97034B (pt) 1998-07-31
IL97545A0 (en) 1992-06-21
FI104047B1 (fi) 1999-11-15
IE910867A1 (en) 1991-09-25
DK0449769T3 (da) 1994-02-21
HUT60768A (en) 1992-10-28
FI911275A0 (fi) 1991-03-14
FI981799A0 (fi) 1998-08-21
FI911275L (fi) 1991-09-17
PL170321B1 (pl) 1996-11-29
NL990008I2 (nl) 1999-10-01
FI19991788L (fi) 1999-08-23
MY106161A (en) 1995-03-31
HU910761D0 (en) 1991-09-30
NZ237434A (en) 1992-08-26
FI981799L (fi) 1998-08-21
HK53797A (en) 1997-05-02
US6521230B1 (en) 2003-02-18
PL289436A1 (en) 1992-02-24
SA92120358B1 (ar) 2004-01-25
EP0449769B1 (fr) 1993-12-15
US6383487B1 (en) 2002-05-07
JPH04316600A (ja) 1992-11-06
AU7290991A (en) 1991-09-19
FI104047B (fi) 1999-11-15
CA2038279C (fr) 1999-03-09
TW213486B (fr) 1993-09-21
JP2585475B2 (ja) 1997-02-26
IL97545A (en) 2000-06-29
PT97034A (pt) 1991-10-31
FI103131B1 (fi) 1999-04-30

Similar Documents

Publication Publication Date Title
CY1977A (en) CD 25 binding molecules
GB2246781A (en) CD3 specific recombinant antibody
GR3020108T3 (en) Monoclonal antibody reactive with a novel HLA determinant on MHC class I molecules and method for activating lymphocytes
DE69429095D1 (de) Humanisierte antikoerper
DK0626447T3 (da) Monoklonale antistoffer og Fv, som er specifikke for CD2-antigen
IE902383L (en) Novel antibodies reactive with human carcinomas
AU3933695A (en) Humanized antibodies to CD38
AU2097692A (en) Method for the production of monoclonal antibodies utilizing a germfree animal
PL313260A1 (en) Monoclonal antibodies having properties making them able to cause apoptosis
EP0521996A4 (en) Catalytic antibody components
EP0257778A3 (en) Apolipoprotein b-specific monoclonal antibodies produced by two novel hybridomas
ES2179824T3 (es) Anticuerpos humanizados reactivos contra el antigeno gpiib/iiia.
EP0338395A3 (en) Monoclonal antibodies to pseudomonas aeruginosa, their production and use
AU1626492A (en) Monoclonal antibodies against the plasmin-antiplasmin complex, a method for the preparation thereof and the use thereof
MY104917A (en) Monoclonal antibodies and methods for diagnosis of phytophora infection
AU8264491A (en) Monoclonal antibodies to leptosphaeria
IL98636A0 (en) Monoclonal antibodies to mycosphaerella species,their production and compositions containing them
BG51640A1 (en) Hybridome cellular line mus musculus balb/c, secreting monoclonal antibody against antigenous determinant, common for the strains " hantaan " and " bulgarian " of the virus of haemorrhagic fever with nephritic syndrome